Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

A 31-year-old uses Minoxidil, RU58841, Reviv Hair Serum, and Ketoconazole shampoo for hair loss but avoids finasteride. They plan to reintroduce red light therapy (LLLT) and Eucapil despite previous shedding concerns.

The user is trying a new hair loss regimen including Spirolactone, Finasteride, oral Minoxidil, microneedling, and various supplements. They are experiencing increased shedding and seeking advice on microneedling and treatment effectiveness.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

User started using topical spironolactone on scalp and face, experienced fever feeling and sluggishness. Asks if side effects are normal or systemic.

A user shared their experience obtaining a finasteride prescription through Lemonaid, highlighting the ease of the process without needing to provide photos. They chose oral finasteride for preventative hair loss treatment due to a family history of baldness and received a year’s supply at a low cost.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

The conversation is about hair loss treatment progress using finasteride and GHK-CU over six months. Users discuss application methods and share experiences with GHK-CU and AHK.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

A 20-year-old female is using finasteride 5mg and spironolactone 100mg for severe hirsutism and is experiencing minor side effects like water weight loss and irregular periods. She is concerned about potential future side effects and hair regrowth on her scalp.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

A user shared positive 6-month results from a hair transplant in Istanbul, receiving 4,450 grafts for the front and mid scalp and 850 for the crown. The procedure cost approximately €2,990.

The user shared progress after 26 months using finasteride and minoxidil, noting a plateau after 18 months but expressing satisfaction with the results. They used a HIMS min/fin spray and finasteride pills, and considered adding tretinoin foam to enhance minoxidil effectiveness.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

The conversation is a humorous and hopeful prayer for the effectiveness of finasteride in combating hair loss. Participants express gratitude and support for the treatment.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

The user plans to use a combination of tretinoin, topical minoxidil, and topical finasteride for hair loss treatment. They seek advice on application order, timing, and tretinoin dosage.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Using roll-on bottles for applying minoxidil and RU58841 improves application efficiency and reduces product waste. Topical treatments are used continuously, except on microneedling days.

The conversation discusses concerns about MVSupplements.com products, specifically the Min+Ru spray and GHK Serum, due to discrepancies in ingredient lists and recent poor feedback. Users also mention a price increase and one user reports no issues with the RU powder.

The conversation is about hair regrowth progress using a combination of treatments: dutasteride, minoxidil, RU58841, ketoconazole, and monthly microneedling. The user reports that microneedling and topical minoxidil had the most impact on their hairline.

The user is experimenting with a zinc sulfate and B6 topical solution called "Zix" for hair loss, alongside using a zinc oxide scalp mask and low-level laser therapy (LLLT). They report minimal hair loss after three months of use and are seeking feedback from others who have tried similar treatments.

A user is considering a hair loss treatment lotion containing minoxidil, adenosine, caffeine, melatonin, and azelaic acid, questioning the interaction between caffeine and adenosine receptors. Another user suggests adding a topical anti-DHT ingredient like spironolactone, noting it should not be taken orally by men.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

The user has been using topical melatonin spray with finasteride and dutasteride to reduce hair shedding but dislikes the lavender scent of their current spray. They are seeking recommendations for a scentless or better-smelling melatonin spray.

A user shared a 7-month update after receiving 3,153 grafts in a hair transplant, noting ongoing growth but some areas still appear sparse and red. They are in contact with the clinic for feedback and are hopeful for further improvement.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.